A heterodimeric glucuronide prodrug for cancer tritherapy: the double role of the chemical amplifier

ChemMedChem. 2011 Dec 9;6(12):2137-41. doi: 10.1002/cmdc.201100355. Epub 2011 Aug 3.

Authors

Marion Grinda¹, Jonathan Clarhaut, Isabelle Tranoy-Opalinski, Brigitte Renoux, Arnaud Monvoisin, Laurent Cronier, Sébastien Papot

Affiliation

¹ Laboratoire de Synthèse et Réactivité des Substances Naturelles, UMR-CNRS 6514, Université de Poitiers, 4 rue Michel Brunet, BP 633, 86022 Poitiers, France.

PMID: 21815268
DOI: 10.1002/cmdc.201100355

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / chemical synthesis
Antineoplastic Agents / chemistry*
Antineoplastic Agents / pharmacology
Benzamides / chemical synthesis
Benzamides / chemistry
Benzamides / toxicity
Cell Line, Tumor
Cell Survival / drug effects
Dimerization
Doxorubicin / analogs & derivatives
Doxorubicin / chemical synthesis
Doxorubicin / chemistry
Doxorubicin / pharmacology
Doxorubicin / toxicity
Drug Screening Assays, Antitumor
Drug Synergism
Glucuronidase / metabolism
Glucuronides / chemistry*
Humans
Neoplasms
Prodrugs / chemical synthesis
Prodrugs / chemistry*
Prodrugs / pharmacology
Pyridines / chemical synthesis
Pyridines / chemistry
Pyridines / toxicity

Substances

Antineoplastic Agents
Benzamides
Glucuronides
Prodrugs
Pyridines
entinostat
Doxorubicin
Glucuronidase